TQA-3605

Main purpose: To evaluate whether TQA3605 tablets combined with oral nucleoside(acid) drugs compared with nucleoside(acid) drug monotherapy can significantly improve the 24 Percentage of subjects with weekly HBV DNA lower than the lower limit of quantitative detection value (<20 IU/mL). Secondary purpose: To evaluate the safety and tolerability of TQA3605 tablets combined with oral nucleos(t)ide drugs in subjects with chronic HBV infection with low viremia; to evaluate the safety and tolerability of TQA3605 tablets combined with oral nucleos(t)ide drugs. The effectiveness of TQA3605 tablets combined with oral nucleos(t)ide drugs in treated subjects with chronic HBV infection and low viremia. Pharmacokinetic (PK) characteristics.